Black Diamond Therapeutics (BDTX)
NASDAQ:BDTX
Top Page
Black Diamond Therapeutics
(NASDAQ:BDTX)
Select Model
Select Model
Rating:52Neutral
Price Target:
$2.50
▲(0.00% Upside)
Action:ReiteratedDate:03/17/26
The score is primarily driven by mixed financial performance: a strong 2025 profitability and free-cash-flow inflection, but offset by zero reported revenue in the provided statements and a multi-year history of losses and cash burn. Limited technical data constrains momentum assessment, while valuation is penalized by a negative P/E and lack of dividend yield.
Positive Factors
Proprietary precision-oncology platform
BDTX's mutation-targeting discovery platform focuses on genetically defined cancer drivers and small molecules for patient subsets. A platform approach creates repeatable R&D productivity, higher target specificity, and stronger partner licensing appeal, supporting durable pipeline value.
Negative Factors
No reported revenue base
The company lacks a recurring revenue base and commercial product sales, so profitability may reflect non-operating items or one-offs. Without operational revenue, earnings quality and durability are hard to underwrite, raising sustainability risk for the business model.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary precision-oncology platform
BDTX's mutation-targeting discovery platform focuses on genetically defined cancer drivers and small molecules for patient subsets. A platform approach creates repeatable R&D productivity, higher target specificity, and stronger partner licensing appeal, supporting durable pipeline value.
Read all positive factors
Black Diamond Therapeutics (BDTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$143.22M
Dividend YieldN/A
Average Volume (3M)611.88K
Price to Earnings (P/E)6.2
Beta (1Y)2.10
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.27
Shares Outstanding57,288,750
10 Day Avg. Volume535,748
30 Day Avg. Volume611,882
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.23
Price to Sales (P/S)1.97
P/FCF Ratio4.67
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue1.96
Enterprise Value/Gross Profit1.97
Enterprise Value/Ebitda5.38
Forecast
1Y Price Target
$10.00Price Target Upside300.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.62
Revenue Forecast (FY)$8.33M
Black Diamond Therapeutics Business Overview & Revenue Model
Company Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets onc...
How the Company Makes Money
BDTX makes money primarily through (1) collaboration and partnership revenue and (2) interest and other income on its cash and investment balances; as a clinical-stage biotech, it does not have a broad, recurring product-sales base. Collaboration ...
Black Diamond Therapeutics Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
63
Positive
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 70.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 69.67M | 0.00 | -437.00K | 0.00 | 0.00 |
| EBITDA | 20.20M | -78.44M | -86.02M | -92.32M | -126.67M |
| Net Income | 22.37M | -69.68M | -82.44M | -91.17M | -125.60M |
Balance Sheet | |||||
| Total Assets | 143.01M | 122.64M | 158.57M | 156.25M | 247.68M |
| Cash, Cash Equivalents and Short-Term Investments | 128.65M | 98.58M | 131.40M | 122.81M | 209.79M |
| Total Debt | 15.07M | 22.19M | 25.30M | 28.14M | 28.46M |
| Total Liabilities | 30.80M | 39.35M | 41.83M | 40.56M | 51.78M |
| Stockholders Equity | 112.21M | 83.28M | 116.74M | 115.69M | 195.90M |
Cash Flow | |||||
| Free Cash Flow | 29.61M | -62.30M | -66.75M | -85.27M | -102.86M |
| Operating Cash Flow | 29.61M | -62.30M | -66.72M | -85.08M | -100.15M |
| Investing Cash Flow | -44.91M | 16.97M | 16.35M | 53.37M | 130.61M |
| Financing Cash Flow | -146.00K | 25.55M | 71.93M | 177.00K | 729.00K |
Black Diamond Therapeutics Technical Analysis
Neutral
2.50
Price Trends
2.30
Positive
2.65
Negative
2.93
Negative
Market Momentum
0.03
Negative
61.61
Neutral
84.68
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDTX, the sentiment is Neutral. The current price of 2.5 is above the 20-day moving average (MA) of 2.22, above the 50-day MA of 2.30, and below the 200-day MA of 2.93, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 61.61 is Neutral, neither overbought nor oversold. The STOCH value of 84.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BDTX.
Black Diamond Therapeutics Risk Analysis
Black Diamond Therapeutics disclosed 81 risk factors in its most recent earnings report. Black Diamond Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Black Diamond Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $333.53M | -11.41 | -77.62% | ― | ― | -29.73% | |
52 Neutral | $143.22M | 6.18 | 17.46% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $872.77M | -18.84 | -63.06% | ― | ― | 59.04% | |
47 Neutral | $233.63M | -1.93 | -51.35% | ― | -80.88% | -388.61% | |
43 Neutral | $146.14M | -8.62 | 25.65% | ― | ― | 18.82% | |
43 Neutral | $57.92M | -2.28 | -55.88% | ― | ― | 1.40% |
* Healthcare Sector Average
BDTX
Black Diamond Therapeutics
2.50
1.12
81.16%
SLS
SELLAS Life Sciences Group
4.86
3.74
333.93%
GALT
Galectin Therapeutics
2.22
0.86
63.24%
VYGR
Voyager Therapeutics
3.92
0.81
26.05%
DMAC
Diamedica Therapeutics
6.19
2.49
67.30%
TIL
Instil Bio
8.54
-6.58
-43.52%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.